Suggestions
Nathan Bryson
Chief Scientific Officer at Field Trip Health
Nathan Bryson is a highly accomplished individual with a diverse academic background and extensive experience in the pharmaceutical and biotechnology industries.
He holds a BSc in Chemistry from Auburn University and has pursued further studies including a PhD in Chemistry with a focus on Radiopharmaceuticals from the prestigious Massachusetts Institute of Technology.
In addition to his PhD, Nathan also completed a NATO Post-doctoral Fellowship in Organometallic synthesis at the University of Strasbourg, and a Post-doctorate in Polymers, once again at the Massachusetts Institute of Technology.
Nathan Bryson has held several significant leadership roles in various organizations over the course of his career. He is currently serving as the Chief Scientific Officer at Field Trip Health, showcasing his expertise in the field of healthcare and wellness.
Prior to his current position, Nathan has demonstrated his leadership abilities as the Chief Scientific Officer at Acerus Pharma, Cynapsus Therapeutics, and Cannasat Therapeutics.
His wealth of experience also includes roles such as Product Development Consultant at NB Consulting, Vice President of Research & Development at Matregen, Executive Director of Research at Bionisis, and as a Senior Chemist and Scientific Animator focusing on Drug Delivery at Flamel Technologies.
Nathan Bryson's career trajectory highlights his strong background in chemistry, pharmaceuticals, and research, making him a valuable asset in the realm of scientific innovation and development.
Highlights
Reunion Neuroscience announces first patient dosed with RE104 in the RECONNECT #postpartumdepression phase 2 trial (NCT06342310).
Congratulations to Robert Alexander, Jasna Hocevar-Trnka and Beatrix Taylor for spearheading the publication about the clinical development of Reunion Neuroscience's novel investigational drug RE104 in #postpartumdepression. Also, many thanks to the entire Reunion Team for past and ongoing contributions to the program. Most exciting is the imminent initiation of recruitment in the RECONNECT TRIAL, a Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Active Dose-Controlled Study evaluating RE104 in moderate and severe PPD patients (NCT063422310).
Read: https://lnkd.in/gq5t_Kzp
Find out more: https://reunionneuro.com/
